Lasolvan Max capsules 75mg, No. 10

Acute and chronic diseases of the respiratory tract, accompanied by the production of viscous sputum:

• acute and chronic bronchitis;

• pneumonia;

• COPD;

• bronchial asthma with difficulty in sputum discharge;

• bronchiectasis.

The drug is taken orally, regardless of food intake. The capsules should be swallowed whole with plenty of liquid. Capsules should not be opened or chewed.

Assign 1 capsule 1 time / day.

If the symptoms of the disease persist within 4-5 days from the start of using the drug, you should consult a doctor.

ambroxol hydrochloride 75 mg

Excipients : crospovidone - 12.55 mg, carnauba wax - 18.31 mg, stearyl alcohol - 110.94 mg, magnesium stearate - 1.2 mg.

• hypersensitivity to ambroxol or other components of the drug;

• I trimester of pregnancy;

• lactation period (breastfeeding);

• age up to 18 years.

The drug LazolvanЃ should be used with caution during pregnancy (II and III trimesters), with renal and / or hepatic insufficiency.

Studies have shown that ambroxol increases secretion in the respiratory tract. Enhances the production of pulmonary surfactant and stimulates ciliary activity. These effects lead to increased mucus flow and transport (mucociliary clearance). Enhancing mucociliary clearance improves sputum flow and relieves coughing.

In patients with COPD, long-term therapy with LazolvanЃ MAX (for at least 2 months) led to a significant decrease in the number of exacerbations. There was a significant decrease in the duration of exacerbations and the number of days of antibiotic therapy.

Indications of the drug Lazolvan Max

Acute and chronic diseases of the respiratory tract, accompanied by the production of viscous sputum:

• acute and chronic bronchitis;

• pneumonia;

• COPD;

• bronchial asthma with difficulty in sputum discharge;

• bronchiectasis.

Dosage regimen

The drug is taken orally, regardless of food intake. The capsules should be swallowed whole with plenty of liquid. Capsules should not be opened or chewed.

Assign 1 capsule 1 time / day.

If the symptoms of the disease persist within 4-5 days from the start of using the drug, you should consult a doctor.

Side effect

Classification of the incidence of side effects (WHO): very often (> 1/10), often (from> 1/100 to <1/10), infrequently (from> 1/1000 to <1/100), rarely (from> 1/10 000 to <1/1000), very rare (from <1/10 000), the frequency is unknown (according to the available data, it is not possible to establish the frequency of occurrence).

From the digestive system: often - nausea; infrequently - dyspepsia, vomiting, diarrhea, abdominal pain.

Allergic reactions: rarely - rash, urticaria; frequency unknown - angioedema, anaphylactic reactions (including anaphylactic shock), pruritus, hypersensitivity reactions.

Contraindications for use

• hypersensitivity to ambroxol or other components of the drug;

• I trimester of pregnancy;

• lactation period (breastfeeding);

• age up to 18 years.

The drug LazolvanЃ should be used with caution during pregnancy (II and III trimesters), with renal and / or hepatic insufficiency.

Application during pregnancy and lactation

Ambroxol crosses the placental barrier.

Preclinical studies have not revealed direct or indirect adverse effects on pregnancy, embryonic / fetal, postnatal development and labor.

Extensive clinical experience with ambroxol after 28 weeks of gestation has not found evidence of a negative effect of the drug on the fetus. However, the usual precautions must be followed when using the drug during pregnancy. It is especially not recommended to take LazolvanЃ MAX in the first trimester of pregnancy. In the II and III trimesters of pregnancy, the use of the drug is possible only if the intended benefit to the mother outweighs the potential risk to the fetus.

Ambroxol can be excreted in breast milk. Despite the fact that undesirable effects were not observed in breastfed children, it is not recommended to use LasolvanЃ MAX during lactation.

Preclinical studies of ambroxol have not shown any negative effects on fertility.

Application for violations of liver function

The drug should be prescribed with caution to patients with hepatic impairment.

Application for impaired renal function

The drug should be prescribed with caution in patients with renal insufficiency.

Application in children

The use of this dosage form under the age of 18 is contraindicated.

special instructions

LazolvanЃ MAX should not be used in combination with antitussives that impede the excretion of sputum.

There are sporadic reports of severe skin lesions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, coinciding with the use of expectorant drugs such as LazolvanЃ MAX. In most cases, they are explained by the severity of the underlying disease and / or concomitant therapy. Patients with Stevens-Johnson syndrome or toxic epidermal necrolysis in the early phase may develop fever, body pain, rhinitis, cough, and sore throat. With symptomatic treatment, it is possible to erroneously prescribe anti-cold remedies. With the development of new lesions of the skin and mucous membranes, the patient should stop treatment with ambroxol and immediately seek medical attention.

In case of impaired renal function, the drug should be used only as directed by a doctor.

Use in pediatrics

For children and adolescents under 18 years of age, it is possible to use other dosage forms of the drug LazolvanЃ (syrup, lozenges, solution for oral administration and inhalation).

Influence on the ability to drive vehicles and mechanisms

There were no cases of the effect of the drug on the ability to drive vehicles and mechanisms. Studies on the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions have not been conducted.

Overdose

The specific symptoms of an overdose in humans have not been described.

There are reports of accidental overdose and / or medical error resulting in symptoms of known side effects of LasolvanЃ MAX: nausea, dyspepsia, diarrhea, vomiting, abdominal pain.

Treatment: artificial vomiting, gastric lavage in the first 1-2 hours after taking the drug, symptomatic therapy.

Drug interactions

No clinically significant adverse drug interactions have been reported.

Ambroxol increases the penetration of amoxicillin, cefuroxime, erythromycin into the bronchial secretions.